# Open Orphan Report major year-on-year revenue growth and profitable H1 2021 performance

- Link: https://www.directorstalkinterviews.com/open-orphan-report-major-year-on-year-revenue-growth-and-profitable-h1-2021-performance/4121023333
- Published: 2021-09-20T07:14:00+01:00
- Author: Giles

**Open Orphan plc** ([LON:ORPH](https://www.directorstalkinterviews.com/company/open-orphan-plc/orph.l)),
a rapidly growing specialist contract research organisation (CRO) and a world leader
in vaccine and antiviral testing using human challenge clinical trials, announced
today its unaudited interim results for the six months ended 30 June 2021. These
results show a continued pattern of profitability from Q4 2020 to a firmly profitable
position delivering a positive EBITDA profit of £2.1 million compared to an EBITDA
loss of £4.1 million in H1 2020. We look forward to achieving record revenues in
2021 in our first full year of EBITDA profitability with recent contract wins and
exceptional pipeline growth fueling revenues into 2022.  

In the past 12 months, the Company has received international recognition and media
attention for its excellence in delivering human challenge studies as a partner 
in the world’s first COVID-19 human challenge characterisation study. The Company
now has a broad range of human challenge study models, focusing on leveraging the
major growth opportunities presenting in infectious and respiratory disease markets,
including RSV, Influenza, Asthma, hRV, COPD and Malaria.

**Profitable Financial Performance in H1 2021:**

·       Continuing from a profitable Q4 2020, the Company has moved the business
to a firmly profitable position with losses consigned to the past

o  242% reported revenue growth in H1 2021 (£21.9m) versus H1 2020 (£6.4m). Other
income grew to £1.2m in H1 2021 from £0.7m in H1 2020

o  EBITDA profit of £2.1m (2020: EBITDA loss of £4.1m)

o  Revenue has more than tripled reflecting six active challenge studies in H1 2021
vs two active challenge studies in H1 2020 and a solid performance in Early Clinical/
Biometry Services

o  In H1 2021, non-COVID-19 related work accounted for 75% of revenues

o  Gross margin has grown from 6% to 28% of revenue, reflecting that the Company
is driving substantial operating leverage through cross selling, restructuring, 
functional integration and operational productivity

·       Cash and cash equivalents were £14.9m at 30 June 2021, primarily reflecting
the operating cashflow cycle of the business with new contract prepayments expected
in H2 2021

·       The Company has executed a share capital re-organisation as an important
enabler to progress the monetisation of non-core assets via distribution of dividend
in specie. In June, it completed the first distribution in specie back to the shareholders
worth £26.2m at 16 September 2021, in relation to the demerging of certain non-core
assets into Poolbeg Pharma Limited (“Poolbeg Pharma”)

|  |  | Open Orphan Plc Group | 
|  |  | (Results as Reported) | 
|  |  |  | 
|  | Unaudited | Unaudited | 
|  | 6 months ended | 6 months ended | 
|  | 30-Jun-21 | 30-Jun-20 | 
|  |  |  | 
| Income Statement | £’000 | £’000 | 
| Revenue (incl. other income) | 23,166 | 7,078 | 
| Gross Profit | 6,041 | 390 | 
| Operating Profit (Loss) after exceptional items | 1,629 | -6,340 | 
| EBITDA before exceptional items | 2,073 | -4,145 |

**Operational highlights**

·      Delivered a strong and growing pipeline of new challenge study contract wins
across a broadening range of challenge studies including influenza, RSV, hRV, Asthma,
etc. Strong growth from Big Pharma clients which will deliver revenues across H2
2021 and into FY 2022

·       Continued to diversify services offering and associated activities such 
as virus manufacturing and lab services enabled by CAP and UKAS accreditations which
are progressing, as well as the development of new challenge study models (Malaria,
COVID-19) as part of its broadening portfolio of challenge models

·      Leveraged its state-of-the-art facilities, including the new 19-bedroom quarantine
facility (Whitechapel Clinic) beside the existing 24-bedroom Queen Mary’s BioEnterprises
Centre facilities also in Whitechapel (QMB). All COVID-19 characterisation study
activities conducted in the 19-bedroom quarantine facility in Royal Free Hospital
in London. We have delivered a record volume of quarantine studies on an increasingly
cost-efficient basis with ample capacity to further grow the business

·      Increased volunteer recruitment capacity through the opening of a new volunteer
screening centre in Manchester and also a new dedicated street level screening facility
in QMB increasing screening capacity to 520 visits per week

·      Disease in Motion® launched as a first step towards its spin off as a standalone
company, with the intention that the value will be delivered to our shareholders
via dividend in specie in the same format as was successfully completed with [Poolbeg Pharma plc](https://www.directorstalkinterviews.com/company/poolbeg-pharma-plc/polb.l).
This unique data-focused platform has multiple infectious disease applications for
a wide variety of end users including big tech, wearables, pharma and biotech companies

**Post-period end**

·      Multiple high value human challenge study contracts signed – £5.7m Influenza
study (September 2021), £8.1m asthma study (August 2021), significant hRV & Influenza
study (July 2021)

·      Successful Phase 2a RSV human challenge studies completed for a top tier 
pharma company and for Bavarian Nordic highlight the value of human challenge studies,
their role in mainstream clinical trial design, and hVIVO’s industry leading position

·      Successfully monetised the first non-core asset via spin-out and AIM IPO 
of Poolbeg Pharma plc through a dividend in specie to Open Orphan shareholders, 
which was non-dilutive to existing shareholdings in the Company

o  As of 16 September 2021, the Open Orphan shareholders’ value in Poolbeg Pharma
plc is £26.2

o  Poolbeg Pharma raised £25m in fresh funds from new investors in an IPO in July
2021

o  Created substantial value for Open Orphan shareholders who received these dividend
shares in Poolbeg Pharma with no income tax due as part of a HMRC approved statutory
demerger

·      Additional 1.3m shares in Open Orphan, valued at £350,000, purchased by Company
Directors (Cathal Friel and Prof. Brendan Buckley)

**Outlook**

·    Post-pandemic, the infectious and respiratory disease market is seeing exponential
growth, with an expected global market value of $250bn by 2025. This is resulting
in a vastly increased market for Open Orphan to test a new range of infectious and
respiratory disease products as the world leader in the provision of human challenge
studies

–     The Company is experiencing a major increase in negotiations, contract wins,
and repeat contract wins with Big Pharma, while also seeing increased wins from 
biotech companies with major deals expected to now sign in Q4 2021 driving revenue
in 2022

–     Open Orphan is expanding its focus and service offering in providing infectious
and respiratory disease challenge studies

·     Full year guidance of c. £40m revenue (incl. other income) with full year 
EBITDA profitability for FY 2021, with non-COVID-19 work expected to represent c.
70% of FY 2021 revenue mix. While 2021 will represent record revenues for the Company
and a return to full year EBITDA profitability, it is somewhat behind analyst expectations
as the anticipated COVID-19 challenge studies will now likely commence in 2022 on
foot of the successfully completed quarantine phase of the Human Challenge Programme
characterisation study

·      Year-end cash balances expected to close in line with the half year position
of £14.9m

·    Targeting revenues in the region of £50m for 2022 in non-COVID-19 work, reflecting
signed contracts and contracts in advanced negotiations, ongoing momentum in the
core business and ongoing market growth. COVID-19 revenue for 2022 will be in addition
to this and will depend on the eventual timing of these studies

·     The Company continues to work towards the monetisation of all remaining non-
core assets and to hand these back to Open Orphan shareholders via dividend in specie
allowing the Company to focus on its core offering

–   These spin-offs / demergers offer an excellent opportunity for shareholders 
to maximise value in separate shareholdings in both exciting pharma product commercialisation
companies, in addition to a profitable and world leading CRO

–      Opportunity to complete spin-off of Disease in Motion® platform along with
plans to monetise the other non-core assets, namely the Company’s 62.6% stake in
PrEP Biopharm, and 49% stake in Imutex Limited

> **Cathal Friel, Executive Chairman of Open Orphan plc commented:**
> **“**Open Orphan has delivered very strong progress both operationally and financially.
> The Company’s H1 2021 revenues grew by 242% versus H1 2020, which continues a 
> pattern of profitability from Q4 2020 and transitions the business to a firmly
> profitable position, having delivered a positive EBITDA profit of £2.1 million
> in H1 2021. The business is now well positioned to capitalise on the significant
> growth in the infectious disease market, which is expected to grow to in excess
> of $250bn by 2025 and we have seen our business development pipeline grow accordingly.
> “I am delighted and hugely satisfied with the fantastic turnaround and team effort
> by everyone in the Open Orphan organisation; they have completely transformed 
> the business following the acquisition of both hVIVO and Venn in the past two 
> years. These two companies are now fully integrated and, in the process, we have
> created the world leader in the testing of vaccines, antivirals and other infectious
> and respiratory disease products using human challenge studies. With a broadening
> portfolio of human challenge studies, we are well placed to continue working with
> Big Pharma and biotechs alike to move their products through the clinic as the
> infectious disease market experiences one of the largest pharmaceutical growth
> cycles ever, with the market expected to grow significantly by 2025.  We look 
> forward to further progress and a profitable H2 as the business continues to attract
> additional clients.
> “Additionally, we will look to provide further shareholder value through the monetisation
> of our non-core assets, as we did post-year end with the successful spin-out, 
> listing and distribution in specie of Poolbeg Pharma plc.”

Share on:
